 So, very briefly and then particularly for the members in the audience in the meeting today who are less familiar with the goals and achievements of IMPC, I want to say a few words about the current achievements of the IMPC, but particularly about the long-term strategy that IMPC have been working on over the last six months or so. And of course the main goal of IMPC is to build the first comprehensive functional catalogue of a mammalian genome through a worldwide consortium effort involving major mouse genetic centres from all over the world. It's hard to think of a major mouse genetic centre that's not involved in IMPC. And the main goals of course, the initial goals of IMPC were to generate a mouse null mutant for every gene in the mouse genome. And importantly of course in terms of future biology and understanding of systems to comprehensively phenotype each of those mice to determine all sorts of phenotype characteristics from development to physiology, biochemistry and so on. But critically to provide an important baseline for exploring gene function and through that a much more profound understanding of the genome landscape and genetic mechanisms with of course the long-term vision that that would really play into our interpretation of human genetic data all the way from rare to complex diseases and of course the analysis of large population genetic data sets that continue to emerge from clinical and human genetics. And increasingly the focus of IMPC as I'll discuss going forward in terms of our long-term strategy over the next 10 years from 2021 to 2030 is to focus increasingly on the functional annotation of human genetic variation. Obviously the null alleles will feed into our understanding of how genetic variation impacts on disease but a more exquisite and finely tuned analysis of what variation in the human genome means for disease and mechanism. We are making tremendous progress with the creation of the null allele resource. Nearly 8,000 genes have been mutated so far. Gold standard mutants which have gone into phenotyping there are over 6,000 lines phenotyped. The take home message is that we have completed a third of the coding genome. In the next two years I expect that we'll have done a half. This huge multidimensional data set is making an enormous difference to our understanding of the genetic landscape which of course is appearing in a large number of high impact IMPC publications. But we want to move on from that and be even more relevant which is part of the aim of today's meeting even more relevant to what's going on in rare disease, Mendelian disease, complex disease communities. This is a rather busy slide and I'll dissect it a bit but this is the ongoing strategic vision for IMPC over phase three and phase four. We're in phase two at the moment which will end in 2021 but the next 10 years. And let me just dissect those particular goals. We obviously are going to complete the generation of a null mouse mutant resource for the coding genome. But most importantly we see ourselves in phase three ramping up the production of coding variants, coding mutations in the mouse associated with rare disease, a genome wide mouse strain resource of human disease associated coding variants. And at the same time design and generate mouse strains that model genetic variation in the non-coding genome which is clearly important to understand in terms of the impact of human genetic variation on disease. And of course as we do with the null mouse mutant resource to phenotype those mouse strains as comprehensively as we can to bring a systems view to the impact of genetic variation on both phenotype and disease. And all of this will only take place if it's highly integrated and enabled and strengthened by working with the various networks, human genome centers, clinical genetics consortia, biobank initiatives. And indeed that is part of our conversation today of how we strengthen the relationship between IMPC and the various initiatives within the human and clinical genetics communities. So from that perspective just to bring more clarity to that vision, this is where we are in phase two at the moment aiming to complete our goal one, our null resource sometime in phase three. But as that null resource is completed increasingly we'll ramp up our production of human coding variants, goal two, human non-coding variants, goal three. Providing all of those mice and providing even more richness to the multi-dimensional data set of mouse genetics that is emerging from IMPC. So our vision is that IMPC through mouse genetics sits importantly at the center of a whole variety of networks, both informational in terms of integration with a slew of databases across the world, integrating with other work on other model organisms. But importantly forging links with all of the major disease networks, clinical genetics consortia and biobanks across the world. Many of those links have already been established but we really need to reinforce that, strengthen them and come to a common vision of how we bring mouse genetics right to the center of ensuring that we really do solve the problem of genetic variation and how it impacts on disease. So I'll leave it there, that's where IMPC is and I hope that gives you a brief picture of how the consortium is contributing to this major goal which of course is integral to everything that we want to do in terms of disease, health and precision medicine. Thank you.